alexa Cytokeratin 19 (CK19) as a Tumor Marker in Pleural Effusion | Open Access Journals
ISSN: 2329-9088
Tropical Medicine & Surgery
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Cytokeratin 19 (CK19) as a Tumor Marker in Pleural Effusion

Mona Z Zaghloul*

Microbiology Unit, Department of Clinical Pathology, Ain Shams University Hospitals, Cairo, Egypt

*Corresponding Author:
Dr. Mona Z Zaghloul
Microbiology Unit, Department of Clinical Pathology
Ain Shams University Hospitals, Cairo, Egypt
Tel: 02-24023494
E-mail: [email protected]

Received Date: September 24, 2014; Accepted Date: September 26, 2014; Published Date: October 03, 2014

Citation: Zaghloul MZ (2015) Cytokeratin 19 (CK19) as a Tumor Marker in Pleural Effusion. Trop Med Surg 3:e122. doi: 10.4172/2329-9088.1000e122

Copyright: © 2015 Zaghloul MZ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Tropical Medicine & Surgery

Pleural effusion is a common clinical presentation. Approximately 20% of pleural effusions are due to malignancy, and 50% of these are due to primary lung cancer [1]. A malignant pleural effusion may be the initial presentation of cancer in 10 to 50% of patients [2]. Cytological examination of malignant effusion is important because it is easy and noninvasive. However, highly suspected cases of malignant effusion with repeated negative cytological findings are sometimes encountered [3]. Several tumor markers in pleural fluid have been evaluated to distinguish malignant effusion from benign e.g. carcinoembryonic antigen (CEA) [4] neuron-specific enolase [5] and cytokeratin 19 [6,7]. During the last 10 years, new immunologic and molecular analytic procedures have been developed to diagnose and characterize minimal residual cancer [8]. Malignant pleural effusions often result from malignant tumors transferring into pleural cavity. On 1998, Lockett et al. [9] had developed keratin-19, c-myc and prolactin inducible protein RT-PCR based method to identify axillary lymph node metastases in patients with breast cancer and thought it appeared to be a readily available and highly sensitive method for detecting breast cancer micrometastases.

Cytokeratins constitute the largest intermediate filament protein subgroup and represent a multigene family with more than 20 different types of polypeptides that are divided into acidic type I(CK9-CK23) and basic type II(CK1-CK8) keratins [10]. Their main function is to maintain the epithelial cell integrity and it has roles in cell signaling, stress responses, and apoptosis [11]. Cytokeratin 19 (CK19) belongs to type I cytokeratins, it is one of the most useful markers for diagnosis and management of tumors. CK19 mRNA is expressed in nearly all the epithelial malignancies as breast cancer [12], lung cancer, colorectal carcinoma [13] untreated early-stage cervical carcinomas [14] and papillary thyroid carcinoma [15]. There has been emerging evidence suggesting that CK19 mRNA detection is strongly associated with the presence of metastases or lung recurrence, particularly after surgery [16]. The detachment of cancer cells from a primary tumor is one of the early sequential events in the metastatic cascade. Therefore, surgeons always worry that the manual manipulation of a tumor during an operation might enhance the shedding of cancer cells into the bloodstream [17]. CK19 mRNA was detected in blood in benign and malignant pleural effusions by quantitative RT-PCR [17]. CYFRA 21-1 is an assay which detects the soluble fragments of cytokeratin 19 by ELISA, immunocytochemistry [13,18] flow cytometry [19] and electrochemiluminescense immunoassay on automatic analyzers [18]. On 2013, Pang et al. [19] evaluated the prognostic significance of the serum tumor markers CYFRA21-1, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), carbohydrate antigen (CA) 125, and CA 19-9 for predicting responses to different chemotherapy regimens in patients with non-small cell lung cancer (NSCLC), they had found that CYFRA 21-1 is the most sensitive of the tumor markers in predicting the response to chemotherapy.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11829
  • [From(publication date):
    March-2015 - Aug 20, 2017]
  • Breakdown by view type
  • HTML page views : 8038
  • PDF downloads :3791

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version